The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Adam Pearson, known for his work as an actor and advocate for rare disease awareness, has publicly shared his experience with neurofibromatosis type 1 (NF1), a genetic condition th ...

Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1, a genetic disorder that causes noncancerous tumors to grow on nerves ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare genetic disorder, which causes tumors to grow in the tissue that covers ...

The single-arm trial focuses on the therapy’s efficacy and safety in NF1 subjects with plexiform neurofibromas. Credit: S_L/Shutterstock. Healx has dosed the first subject in the open-label Phase II ...

Cambridge biotech Healx stands on the cusp of history after dosing the first patient with a rare and deadly cancer with a ...